Navigation Links
Key Trigger Of Opioid Withdrawal Symptoms Found

Researchers have discovered an important chemical in the brain's neuronal machinery that triggers some of the withdrawal symptoms of opioid drugs like morphine and heroin.

They believe that drugs to inhibit the chemical--called a transporter--could relieve some of the early physical symptoms of withdrawal, such as teeth-chattering, uncontrolled shaking, and jumpiness. Such drugs could become part of the arsenal of medicines and behavioral techniques aimed at helping addicts kick their habits.


To zero in on the machinery underlying withdrawal symptoms, researchers led by Elena Bagley and Macdonald Christie of the Pain Management Research Institute at Royal North Shore Hospital (a division of the University of Sydney) performed biochemical studies on brain slices from mice that had been treated with morphine. Their objective was to understand what happens to a particular region of the midbrain--called the periaqueductal gray (PAG)--known to be involved in such withdrawal symptoms. Opiate addiction inhibits neuron activity in this region, which alters the neuronal machinery to compensate for this inhibition. Upon opiate withdrawal, the neurons rebound, becoming hyperactive.

The scientists' analysis revealed that a transporter molecule for the neurotransmitter GABA was responsible for the electrical abnormalities that produce a hyperexcitability in the neurons. Neurotransmitters are the molecular ammunition that one neuron fires at its neighbor to trigger a nerve impulse in the neighbor. Propagation of such nerve impulses through the networks of neurons in the brain is the basis of all neural activity. Transporter molecules are the proteins that retrieve neurotransmitter molecules from the spaces between neurons after they trigger nerve impulse, to reload the neuron for its next signaling burst.

Bagley and her colleagues also discovered that a molecular switch called protein kinase A was part of the triggering machinery involved in activating the abnormal GABA transporter activity.

Importantly, the researchers found that drugs that inhibit either the GABA transporter activity or protein kinase A eliminate the hyperexcitability of the PAG neurons in the mouse brain slices.

The researchers cited other studies showing that treatment with opioids also altered levels of the transporter for the neurotransmitter glutamate, "suggesting that neurotransmitter transporters may prove to be useful targets for management of opioid dependence," they wrote. The researchers also wrote that, since GABA is a neurotransmitter that inhibits nerve impulses, drugs to inhibit the GABA transporter "could produce their therapeutic effect through altering extracellular GABA concentrations as well as directly altering the excitability of GABAergic neurons."

###

Elena E. Bagley, Michelle B. Gerke, Christopher W. Vaughan, Stephen P. Hack, and MacDonald J. Christie: "GABA Transporter Currents Activated by Protein Kinase A Excite Midbrain Neurons during Opioid Withdrawal"

Publishing in Neuron, Volume 45, Number 3, February 3, 2005, pages 433?45. http://www.neuron.org


'"/>

Source:Cell Press


Related biology news :

1. Bacteria in Household Dust May Trigger Asthma Symptoms
2. Opiates Better Than Sedatives For Treating Newborns In Withdrawal
3. Menopause Symptoms May Come Back After Stopping Menopausal Hormone Therapy
4. Synthetic Protein Eases Arthritis Symptoms in Mice
5. Potential Drug Target For Treating Cocaine Abuse Found
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/9/2018)... N.Y. (PRWEB) , ... August 08, 2018 , ... ... largest training, research and marketing companies, who helps physicians bring the latest regenerative ... training on Friday and Saturday, October 5-6, 2018 in White Plains, NY. ...
(Date:8/7/2018)... ... August 06, 2018 , ... BioMedGPS announces the launch ... Inspired by its medical device customers, BioMedGPS teamed up with a usability expert ... changes, SmartTRAK 3.0 touts a cleaner look, easier navigation and improved functionality. ...
(Date:8/2/2018)... ... August 02, 2018 , ... RxS LLC (“RxS”), a privately ... announced that Mark Jara, principal of the organization, has been named to PharmaVOICE ... Individuals named to PharmaVOICE 100 are leaders who drive the industry forward and ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ... developed and is continually updated by a talented scientific team that includes geneticists, ... provides: , 1. Information on the medical impact of a patient’s genetic ...
(Date:8/9/2018)... ... , ... Since their establishment in 2012, ambitions have been high at Nicoya ... size from last year, the company is thrilled to announce the release of their ... at a private product launch event during the annual Protein Society Symposium in Boston ...
(Date:8/9/2018)... ... August 09, 2018 , ... Rockland ... and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed ... was published online on August 9, 2018 and will be printed in the ...
(Date:8/7/2018)... BOSTON (PRWEB) , ... August 06, 2018 , ... ... life sciences and diagnostics companies, announces the placement of Dr. Paul Harney as ... delivering Prescient’s North America growth strategy and enhancing client satisfaction. He was also ...
Breaking Biology Technology: